Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564432/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688431158886400 |
|---|---|
| author | F. H. van Bruggen H. J. Luijendijk |
| author_facet | F. H. van Bruggen H. J. Luijendijk |
| author_sort | F. H. van Bruggen |
| collection | DOAJ |
| format | Article |
| id | doaj-art-2678ade8302a4b49ba93fd79810b3d69 |
| institution | DOAJ |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-2678ade8302a4b49ba93fd79810b3d692025-08-20T03:22:00ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-06-011210.3389/fcvm.2025.15644321564432Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisalF. H. van BruggenH. J. Luijendijkhttps://www.frontiersin.org/articles/10.3389/fcvm.2025.1564432/fulltype 2 MIPCSK 9 inhibitorsGLP 1 analogSLGT inhibitorsefficacy outcomessafety outcomes |
| spellingShingle | F. H. van Bruggen H. J. Luijendijk Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal Frontiers in Cardiovascular Medicine type 2 MI PCSK 9 inhibitors GLP 1 analog SLGT inhibitors efficacy outcomes safety outcomes |
| title | Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal |
| title_full | Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal |
| title_fullStr | Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal |
| title_full_unstemmed | Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal |
| title_short | Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal |
| title_sort | type 2 mi a legitimate efficacy endpoint in cardiovascular trials a critical appraisal |
| topic | type 2 MI PCSK 9 inhibitors GLP 1 analog SLGT inhibitors efficacy outcomes safety outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564432/full |
| work_keys_str_mv | AT fhvanbruggen type2mialegitimateefficacyendpointincardiovasculartrialsacriticalappraisal AT hjluijendijk type2mialegitimateefficacyendpointincardiovasculartrialsacriticalappraisal |